Eli Lilly Other Receivables decreased by 28.5% to $2.40B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 5.5%, from $2.27B to $2.40B. Over 5 years (FY 2020 to FY 2025), Other Receivables shows an upward trend with a 17.8% CAGR.
Significant fluctuations may indicate one-time events or changes in non-operating business activities.
This category includes miscellaneous claims for cash that are not derived from standard trade sales of pharmaceutical pr...
Varies widely based on the complexity of a company's tax structure and collaborative R&D agreements.
other_receivables| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.07B | $1.11B | $1.45B | $1.48B | $1.31B | $1.61B | $1.66B | $1.50B | $1.66B | $2.20B | $2.25B | $2.13B | $2.05B | $1.76B | $2.27B | $1.97B | $3.04B | $3.35B | $2.40B |
| QoQ Change | — | +3.5% | +30.9% | +2.0% | -11.8% | +23.1% | +3.3% | -10.0% | +10.7% | +32.7% | +2.2% | -5.2% | -3.6% | -14.3% | +29.2% | -13.4% | +54.3% | +10.4% | -28.5% |
| YoY Change | — | — | — | — | +21.8% | +44.9% | +14.3% | +0.9% | +26.6% | +36.5% | +35.0% | +42.2% | +23.9% | -20.0% | +1.1% | -7.6% | +48.0% | +90.7% | +5.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.